AlzStack:使用可解释的人工智能系统预测早期发病的阿尔茨海默氏症,使用多种数据平衡技术.
Venkata Aditi Modali1, Manohar Pavanya2, R Vijaya Arjunan1
1Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
Global epidemiology
|January 1, 2026
概括
早期发现阿尔茨海默氏症 (AD) 是改进了AlzStack,一个新的AI模型. 这种组合分类器使用各种患者数据准确地识别AD,优于传统方法以获得更好的患者结果.
科学领域:
- 人工智能在医学中的应用
- 神经学 神经学
- 机器学习用于医疗保健
背景情况:
- 阿尔茨海默病 (AD) 诊断依赖于通常耗时,昂贵和不一致的方法.
- 早期发现AD对于及时干预和改善患者预后至关重要.
研究的目的:
- 开发和评估AlzStack,这是一个软投票组合模型,用于准确地分类阿尔茨海默病.
- 将AlzStack的性能与传统的诊断方法和其他组合方法进行比较.
主要方法:
- 利用了包括人口统计,医学,生活方式和认知变量在内的2,149名患者的综合数据集.
- 实施了5倍交叉验证管道,随机化超参数调整和先进的重新采样技术 (SMOTE,ADASYN,边界SMOTE,SVMSMOTE) 以解决类不平衡问题.
- 采用可解释的人工智能 (XAI) 方法来解释模型的可解释性.
主要成果:
- AlzStack实现了高性能指标:94.27%的AUC,93.26%的精度,89.17%的精度,92.11%的回忆和90.61%的F1得分.
- 软投票组合分类器的表现优于堆叠和硬投票组合.
- XAI方法确定了关键的预测特征,如MMSE得分,功能测量和行为标记.
结论:
- 阿尔兹斯塔克在早期发现阿尔茨海默病方面表现出强大的预测性能.
- 该模型为AD诊断提供了可解释的见解,增强了其作为医疗保健决策支持工具的实用性.
- 这种人工智能方法为传统的AD诊断方法提供了更有效,更准确的替代方案.
更多相关视频
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.9K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.5K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
